All GLG News Analyses Filed Under: Ophthalmology

The Next Big Thing in Cataract and Lens Based Surgery: The Light Adjustable Lens (LAL)

April 7, 2008

Analysis by: GLG Expert Contributor

Analysis of:Pilot trial for toric correction with light-adjustable lens yields promising early results | ophthalmologytimes.modernmedicine.com

The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery.  The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine tune the outcome as desired by the patient or the surgeon.  There is no other similar technology like it in clinical studies.  

Visudyne teraphy may play a new role in AMD treatment

April 7, 2008

Analysis by: GLG Expert Contributor

Analysis of:Positive Results From Visudyne (R) Combination Therapy Study Reported at Annual Macula Society Conference | www.pipelinereview.com

1. AMD 2. Anti VEG 3. Visudyne

Truth vs. Profits

March 31, 2008

Analysis by: GLG Expert Contributor

Analysis of:Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com

In many respects, it is good that this trial was done.  For many years, retinal physicians had used Avastin injections preferentially over Lucentis for the treatment of AMD because of the vast difference in cost.

Robert DevenyiProfessor and Chief of OphthalmologyUNIVERSITY OF TORONTO

It is morally reprehensible that the NEI was forced to act and create the CATT trial

March 11, 2008

Analysis of:Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com

I agree...the present situation is really quite absurd...in most practices...IF a third party is willing to pay for Lucentis...patients usually get Lucentis...if patients have to pay themselves...they usually receive Avastin...despite there not being a shred of convincing evidence that Lucentis is superior to Avastin...in fact...most retinal specialists suspect that Avastin might will be superior...due to a longer duration of effect...and thus requiring less frequent injections...It is morally reprehensible that the CATT trial is happening because the NEI had to step in...Genentech refused to do the right thing and compare their two medicines...instead...and even worse...they tried...last November...unsuccessfully...to block compounding pharmacies from supplying Avastin to retinal specialists...

Decreasing the risk of complications in the treatment of wet AMD.

March 5, 2008

Analysis by: GLG Expert Contributor

Analysis of:MacuSight Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration | pharmalive.com

1. Wet AMD. 2. Macular edema. 3. Intravitreal injection.

Choosing the best treatment for wet AMD.

March 5, 2008

Analysis by: GLG Expert Contributor

Analysis of:Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com

1. Lucentis. 2. Avastin. 3. Cost.

Effect of Punctal Plugs in Patients with Low Refractive Errors Considering Refractive Surgery

February 29, 2008

Analysis by: GLG Expert Contributor

Analysis of: Effect of Punctal Plugs in Patients with Low Refractive Errors Considering Refractive Surgery | www.journalofrefractivesurgery.com

This was a retrospective clinical study of 21 eyes from 12 patients who identified themselves as being dissatisfied with their visual acuity and were interested either in initial or enhancement refractive surgery in order to improve their acuity. Uncorrected visual acuity was documented in each eye. If there was a positive tear normalization test, indicating dry eyes, silicone punctal plugs were placed in the lower lids of both eyes. Uncorrected visual acuity and patient subjective responses were assessed at least one month later.

Sirolimus (Macusight) is Latest Player to Enter the AMD Market

February 28, 2008

Analysis by: GLG Expert Contributor

Analysis of:MacuSight Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration | pharmalive.com

Sicrolimus is a novel agent that has a broad range of activities that is entering the Ophthalmic Arena.  Phase I Data has shown its safety profile in treating two large markets: Age Related Macular Degeneration and Diabetic Macular Edema.  Given its success in cardiology, it is a promising agent with much potential.

Zylet (Bausch & Lomb) as as good and safer than Tobradex (ACL) for Blepharitis.

February 28, 2008

Analysis by: GLG Expert Contributor

Analysis of:Bausch & Lomb Announces Positive Clinical Results for Zylet in a Comparison of Safety and Efficacy with Tobradex in the Treatment of Blepharokeratoconjunctivitis | pharmalive.com

This study shows that Bausch and Lomb's Zylet is as good and safer than Alcon's Tobradex for the management of Blepharitis.  Blepharitis is a large problem affecting many patients.  This could be a large market opportunity.

Biovitrum's BVT.28949 Glaucoma Medication Results are Disappointing

February 28, 2008

Analysis by: GLG Expert Contributor

Analysis of:Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com

Biovitrum reports Phase II results of its new glaucoma medication. Although the mechanism of action of this glaucoma drug is novel and targets the site of disease in glaucoma, its clinical results are very disappointing.  A 10% reduction in intraocular pressure is not enough to make a clinical impact.

Previous Page : 234567891011Next61 to 70 of 304